Defence Research and Development Laboratory

10x Genomics Surpasses 100 Xenium Analyzer Shipments

Retrieved on: 
Tuesday, August 29, 2023
Tissue, Adelaide, University, FISH, Cancer Institute, Rosenbergia xenium, Genomics, Defence Research and Development Laboratory, Bay Adelaide Centre, 10x Genomics, Research, Research fellow, Genetic distance, RNA, Multiple sclerosis, Cell, H&E, Associate, IHC, Chemistry, Colorectal cancer, B cell, Professor, Data analysis, Melanoma, Icahn Genomics Institute, Biology, Basal-cell carcinoma, Growth, SNV, Health, Environment, Rest, MD Anderson Cancer Center, Gene, Disease, Medical imaging, Vaccine

PLEASANTON, Calif., Aug. 29, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has shipped more than 100 Xenium Analyzer instruments in the eight months since the platform's launch. The milestone reflects strong customer demand for the Xenium platform, which is increasingly recognized as the best performing system for in situ analysis.

Key Points: 
  • Rapid growth and adoption of Xenium Analyzer demonstrates strength of company's innovation engine, broad commercial reach and operational scale
    PLEASANTON, Calif., Aug. 29, 2023 /PRNewswire/ -- 10x Genomics , Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has shipped more than 100 Xenium Analyzer instruments in the eight months since the platform's launch.
  • I firmly believe Xenium has the potential to be one of the most transformative technologies in our industry in decades."
  • With the vast majority of the first 100 Xenium shipments already installed, researchers are using the system to successfully analyze a variety of tissues and sample types, including fresh frozen, FFPE and tissue microarrays, and reveal new insights into health and disease.
  • Also in 2024, 10x Genomics expects to launch an in-line protein assay to combine with the RNA assays on the exact same tissue section.

Get-A-Grip Glove Adds Xylazine Resistance to Better Protect First Responders

Retrieved on: 
Wednesday, July 26, 2023
Xylazine, Public, Gastric acid, Multimedia, Heroin, Get a Grip, Defence Research and Development Laboratory, DEA, PH, Risk, ARDL, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Fentanyl, Food, Medical device, Drug

PH&S Products Get-A-Grip Nitrile Disposable Glove adds Xylazine resistance to better protect first responders.

Key Points: 
  • PH&S Products Get-A-Grip Nitrile Disposable Glove adds Xylazine resistance to better protect first responders.
  • Akron Rubber and Development Laboratories (ARDL) testing showed the Get-A-Grip two-tone, powder-free nitrile glove with a diamond pattern maintained resistance to xylazine for up to 240 minutes of exposure.
  • This test proves the Get-A-Grip glove will provide protection from xylazine exposure for law enforcement officers, first responders, healthcare workers, and others who might come into accidental contact with the substance.
  • Adding xylazine resistance to a product that already includes resistance to the big three—fentanyl, heroin, and gastric acid—will help keep more professionals safe as they increasingly come in contact with these dangerous substances.

Advanced Cell Engineering Unveils New State-of-the-Art Battery Laboratory

Retrieved on: 
Tuesday, July 11, 2023
Lithium, Electric vehicle battery, Developer, Electric vehicle, Defence Research and Development Laboratory, Research, LFP, ACE, Advanced Cell Therapeutics, Renewable energy, Education minister

STUART, Fla., July 11, 2023 /PRNewswire/ -- Advanced Cell Engineering (ACE) , a Developer and Licensor of Advanced Lithium-Ion Technologies for the Electric Vehicle (EV) Market, proudly announces the opening of their new Battery Research and Development Laboratory.

Key Points: 
  • STUART, Fla., July 11, 2023 /PRNewswire/ -- Advanced Cell Engineering (ACE) , a Developer and Licensor of Advanced Lithium-Ion Technologies for the Electric Vehicle (EV) Market, proudly announces the opening of their new Battery Research and Development Laboratory.
  • "We are thrilled to announce the opening of our expanded Battery Laboratory," said John Kaufman, Founder & CEO of Advanced Cell Engineering.
  • Key areas of focus in the laboratory will be:
    The establishment of this new laboratory represents an exciting chapter in Advanced Cell Engineering's journey.
  • The company remains committed to advancing the pace of battery innovation and contributing to a sustainable future.

Northeastern Dairy Product Innovation Competition Launches with $365,000 in Awards

Retrieved on: 
Thursday, February 2, 2023
Milk, Farmer, Cornell University, Food safety, Entrepreneurship, Food processing, Defence Research and Development Laboratory, CREA, Workforce Innovation in Regional Economic Development, Partnership, Faculty, Statutory college, CALS, Dairy, Management, Upstate New York, Food

ITHACA, N.Y., Feb. 2, 2023 /PRNewswire/ -- A new competition for producers of value-added dairy products is now open for applications. The Northeastern Dairy Product Innovation Competition supports food innovators in launching products made from dairy ingredients produced in the Northeast and gives dairy entrepreneurs, including those making products on organic and small farms, access to entrepreneurial and technical support.

Key Points: 
  • The Northeastern Dairy Product Innovation Competition supports food innovators in launching products made from dairy ingredients produced in the Northeast and gives dairy entrepreneurs, including those making products on organic and small farms, access to entrepreneurial and technical support.
  • The competition is produced by Cornell's Center for Regional Economic Advancement (CREA) in partnership with the Northeast Dairy Foods Research Center (NDFRC).
  • This competition, along with our specialized grants for dairy processors, creates more pathways for regional dairy processing that benefits farmers, consumers, and our regional economy."
  • To learn more about the Northeastern Dairy Product Innovation Competition, visit: www.dairyinnovation.org
    To learn more about the Cornell Center for Regional Economic Advancement, visit: https://crea.cornell.edu/

Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals

Retrieved on: 
Tuesday, February 8, 2022
Biotechnology, FDA, Infectious Diseases, Health, Pharmaceutical, NDA, News, Growth, OTCQX, Metronidazole, Death, File, Laboratory, Intention, Company, Capsule, Infection, Sale, Therapy, FDA, Patient, Defence Research and Development Laboratory, CGMP, Tablet, TSX, Drug development, LLC, Pharmaceutical industry

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company focused on drug development for infectious diseases, announced today it has amended its agreement with Saptalis Pharmaceuticals LLC (Saptalis), a New York-based specialty pharmaceuticals company, to expand the territories in which Saptalis will commercialize ATI-1501 , Appilis liquid oral reformulation of the antibiotic metronidazole.

Key Points: 
  • Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company focused on drug development for infectious diseases, announced today it has amended its agreement with Saptalis Pharmaceuticals LLC (Saptalis), a New York-based specialty pharmaceuticals company, to expand the territories in which Saptalis will commercialize ATI-1501 , Appilis liquid oral reformulation of the antibiotic metronidazole.
  • Under the terms of the amended agreement, Saptalis will assume responsibility for development and commercialization of ATI-1501 in Europe and Latin America (collectively, the Expanded Territories).
  • Saptalis and Appili are developing ATI-1501 to provide a ready-to-use, taste-masked liquid oral dose form of metronidazole for the growing number of patients with difficulty swallowing.
  • Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections.

AI-powered Solutions to Create an Ecosystem of Connected Laboratories for Superior Collaborations and Efficiencies

Retrieved on: 
Wednesday, September 22, 2021
Artificial intelligence, Efficiency, Frost & Sullivan, Solution, Thermo Fisher Scientific, Software, Frost, Big data, Defence Research and Development Laboratory, Senior, Risk, Fourth Industrial Revolution, Technology, Automation, Research, Industry, R, Safety, Laboratory, Senior Consultant, Ecosystem, Pharmacy, Renewable energy, Medical device

SAN ANTONIO, Sept. 22, 2021 /PRNewswire/ -- The pandemic affected laboratory output regarding staffing and supply chains. Reduced on-site personnel and the constant risk of consumable and equipment shortages are driving the need for automation, cross-training, and remote collaboration. Scientists, vendors, and other stakeholders demand a push toward the "Laboratory of the Future," which leverages technology to improve productivity and innovation.

Key Points: 
  • Reduced on-site personnel and the constant risk of consumable and equipment shortages are driving the need for automation, cross-training, and remote collaboration.
  • Scientists, vendors, and other stakeholders demand a push toward the "Laboratory of the Future," which leverages technology to improve productivity and innovation.
  • The article also highlights the role of artificial intelligence (AI) solutions to enable a smart laboratory ecosystem.
  • Form strategic partnerships and nurture collaborations with global laboratories to speed therapeutic development from hypothesis to final-stage clinical studies via digital connections.

AI-powered Solutions to Create an Ecosystem of Connected Laboratories for Superior Collaborations and Efficiencies

Retrieved on: 
Wednesday, September 22, 2021
Artificial intelligence, Efficiency, Frost & Sullivan, Solution, Thermo Fisher Scientific, Software, Frost, Big data, Defence Research and Development Laboratory, Senior, Risk, Fourth Industrial Revolution, Technology, Automation, Research, Industry, R, Safety, Laboratory, Senior Consultant, Ecosystem, Pharmacy, Renewable energy, Medical device

SAN ANTONIO, Sept. 22, 2021 /PRNewswire/ -- The pandemic affected laboratory output regarding staffing and supply chains. Reduced on-site personnel and the constant risk of consumable and equipment shortages are driving the need for automation, cross-training, and remote collaboration. Scientists, vendors, and other stakeholders demand a push toward the "Laboratory of the Future," which leverages technology to improve productivity and innovation.

Key Points: 
  • Reduced on-site personnel and the constant risk of consumable and equipment shortages are driving the need for automation, cross-training, and remote collaboration.
  • Scientists, vendors, and other stakeholders demand a push toward the "Laboratory of the Future," which leverages technology to improve productivity and innovation.
  • The article also highlights the role of artificial intelligence (AI) solutions to enable a smart laboratory ecosystem.
  • Form strategic partnerships and nurture collaborations with global laboratories to speed therapeutic development from hypothesis to final-stage clinical studies via digital connections.